Financial Review: 111 (YI) & The Competition

Earnings and Valuation

This table compares 111 and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
111	$1.97 billion	-$1.42 million	-12.16
111 Competitors	$418.70 million	-$61.27 million	5.56

111 has higher revenue and earnings than its peers. 111 is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

111 has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, 111’s peers have a beta of 1.84, meaning that their average stock price is 84% more volatile than the S&P 500.

Institutional & Insider Ownership

21.3% of 111 shares are held by institutional investors. Comparatively, 42.3% of shares of all “MEDICAL INFO SYS” companies are held by institutional investors. 43.9% of 111 shares are held by insiders. Comparatively, 18.3% of shares of all “MEDICAL INFO SYS” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares 111 and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
111	-0.48%	N/A	-2.45%
111 Competitors	-194.24%	-97.38%	-20.44%

Summary

111 beats its peers on 6 of the 9 factors compared.

111 Company Profile

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.